ImmuPharma (LON:IMM) Shares Up 29% - What's Next?

Key Points

• ImmuPharma's stock price increased by 29%, reaching a high of GBX 10.50 during trading, significantly higher than its previous close of GBX 8.06.
• The company has a market capitalization of £51.97 million and has reported a negative P/E ratio of -1,168.54 along with a net margin of 3,519.56%.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, Lupuzor™, aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded up 29% during mid-day trading on Tuesday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.40 ($0.14). 29,117,717 shares changed hands during trading, an increase of 290% from the average session volume of 7,457,263 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Price Performance

The firm has a market cap of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The stock has a 50-day moving average of GBX 3.12 and a 200-day moving average of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.